CO2018011972A2 - Receptores de células t - Google Patents

Receptores de células t

Info

Publication number
CO2018011972A2
CO2018011972A2 CONC2018/0011972A CO2018011972A CO2018011972A2 CO 2018011972 A2 CO2018011972 A2 CO 2018011972A2 CO 2018011972 A CO2018011972 A CO 2018011972A CO 2018011972 A2 CO2018011972 A2 CO 2018011972A2
Authority
CO
Colombia
Prior art keywords
tcrs
cell receptors
mage
gvydgrehtv
tcr
Prior art date
Application number
CONC2018/0011972A
Other languages
English (en)
Inventor
Conor Hayes
Linda Hibbert
Nathaniel Liddy
Tara Mahon
Marine Raman
Original Assignee
Immunocore Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunocore Ltd filed Critical Immunocore Ltd
Publication of CO2018011972A2 publication Critical patent/CO2018011972A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a receptores de células T (TCR) que se unen al péptido restringido al HLA-A*02 GVYDGREHTV (SEQ ID NO: 1) derivado del antígeno de cáncer de línea germinal MAGE A4. Dichos TCR pueden comprender mutaciones no naturales dentro de los dominios variables alfa y/o beta con respecto a un TCR de MAGE A4 nativo. Los TCR de la invención son particularmente adecuados para uso como nuevos reactivos inmunoterapéuticos para el tratamiento de enfermedades malignas
CONC2018/0011972A 2016-04-08 2018-11-02 Receptores de células t CO2018011972A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201606009 2016-04-08
PCT/GB2017/050985 WO2017175006A1 (en) 2016-04-08 2017-04-07 T cell receptors

Publications (1)

Publication Number Publication Date
CO2018011972A2 true CO2018011972A2 (es) 2019-02-08

Family

ID=58548761

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0011972A CO2018011972A2 (es) 2016-04-08 2018-11-02 Receptores de células t

Country Status (29)

Country Link
US (2) US11505590B2 (es)
EP (2) EP4023668A1 (es)
JP (1) JP7254519B2 (es)
KR (1) KR102473964B1 (es)
CN (1) CN109563148B (es)
AU (2) AU2017246693B2 (es)
BR (1) BR112018070741A2 (es)
CA (1) CA3020214A1 (es)
CL (1) CL2018002859A1 (es)
CO (1) CO2018011972A2 (es)
CR (1) CR20180531A (es)
DK (1) DK3440105T3 (es)
ES (1) ES2914648T3 (es)
HR (1) HRP20220865T1 (es)
HU (1) HUE059159T2 (es)
IL (2) IL308831A (es)
LT (1) LT3440105T (es)
MA (1) MA44608B1 (es)
MD (1) MD3440105T2 (es)
MX (1) MX2018012318A (es)
MY (1) MY198621A (es)
PE (2) PE20240693A1 (es)
PH (1) PH12018502158A1 (es)
PL (1) PL3440105T3 (es)
PT (1) PT3440105T (es)
RS (1) RS63371B1 (es)
SG (1) SG11201808797XA (es)
SI (1) SI3440105T1 (es)
WO (1) WO2017175006A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3440102B1 (en) * 2016-04-08 2024-06-05 Adaptimmune Limited T cell receptors
CN116239669A (zh) 2016-04-08 2023-06-09 艾达普特免疫有限公司 T细胞受体
JP2020537515A (ja) 2017-10-03 2020-12-24 ジュノー セラピューティクス インコーポレイテッド Ｈｐｖ特異的結合分子
WO2019133443A1 (en) * 2017-12-28 2019-07-04 Janux Therapeutics, Inc. Modified t cell receptors
GB201803750D0 (en) 2018-03-08 2018-04-25 Immunocore Ltd Method
BR112020020245A2 (pt) * 2018-04-05 2021-04-06 Editas Medicine, Inc. Métodos de produzir células expressando um receptor recombinante e composições relacionadas
PT3911298T (pt) 2019-01-17 2024-02-19 Immunocore Ltd Formulações
GB201901305D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Specific binding molecules
GB201901306D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Multi-domain binding molecules
EP3714941A1 (en) * 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
BR112021025548A2 (pt) * 2019-06-18 2022-05-17 Regeneron Pharma Receptores de células t mage-a4 e métodos de uso dos mesmos
CA3142513A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
AU2020406085A1 (en) 2019-12-18 2022-05-26 F. Hoffmann-La Roche Ag Antibodies binding to HLA-A2/MAGE-A4
TWI832035B (zh) 2020-02-14 2024-02-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
WO2021236548A1 (en) * 2020-05-18 2021-11-25 Board Of Regents, The University Of Texas System Engineered t cell receptors and methods of use
MX2022014636A (es) * 2020-05-19 2023-02-23 Amgen Inc Construcciones de unión a mageb2.
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
AU2022233285A1 (en) 2021-03-09 2023-10-19 Cdr-Life Ag Mage-a4 peptide-mhc antigen binding proteins
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
CN118139858A (zh) 2021-10-28 2024-06-04 吉利德科学公司 吡地嗪-3(2h)-酮衍生物
KR20240097895A (ko) 2021-10-29 2024-06-27 길리애드 사이언시즈, 인코포레이티드 Cd73 화합물
TW202328212A (zh) 2021-12-01 2023-07-16 英商英美偌科有限公司 Ｍａｇｅ—ａ４陽性癌症之治療
CA3239528A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CA3237577A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
AU2023233730A1 (en) 2022-03-17 2024-09-26 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023205719A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Kras g12d modulating compounds
CN117106060A (zh) * 2022-05-17 2023-11-24 香雪生命科学技术（广东）有限公司 一种识别mage的高亲和力t细胞受体及其应用
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
WO2024038198A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
WO2024038193A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
WO2024038183A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
WO2024038165A1 (en) 2022-08-18 2024-02-22 Immunocore Ltd T cell receptor fusion proteins specific for mage a4
US20240091262A1 (en) 2022-09-14 2024-03-21 Cdr-Life Ag Mage-a4 peptide dual t cell engagers
WO2024137852A1 (en) 2022-12-22 2024-06-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0977886A4 (en) 1997-03-07 2002-10-23 Sunol Molecular Corp FUSION PROTEINS, WHICH CONTAIN A BACTERIOPHAGE ENVELOPE PROTEIN AND A SINGLE CHAIN T-CELL RECEPTOR
KR100712256B1 (ko) 1997-10-02 2007-04-27 알토 바이오사이언스 코포레이션 가용성 단일쇄 ｔ-세포 수용체 단백질
EP1117679B9 (en) 1998-10-02 2010-07-07 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
EP1247095B1 (en) 1999-12-06 2008-10-15 Board Of Trustees Of The University Of Illinois High affinity tcr proteins and methods
AU2001232204A1 (en) 2000-02-22 2001-09-03 Ahuva Nissim Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof
PL208712B1 (pl) 2001-08-31 2011-05-31 Avidex Ltd Rozpuszczalny receptor komórek T (sTCR), rozpuszczalna αβ-postać receptora komórek T (sTCR), wielowartościowy kompleks receptora komórek T (TCR), sposób wykrywania kompleksów MHC-peptyd, środek farmaceutyczny zawierający sTCR i/lub wielowartościowy kompleks TCR, cząsteczka kwasu nukleinowego, wektor, komórka gospodarz, sposób otrzymywania całości lub części łańcucha α TCR albo całości lub części łańcucha β TCR, sposób otrzymywania rozpuszczalnego receptora komórek T (sTCR), sposób otrzymywania rozpuszczalnej αβ-postaci receptora komórek T (sTCR) oraz sposób wykrywania kompleksów MHC-peptyd
WO2004023973A2 (en) * 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
JP4975324B2 (ja) 2002-11-09 2012-07-11 イムノコア リミテッド Ｔ細胞レセプターディスプレイ
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
NZ561338A (en) 2005-04-01 2010-04-30 Immunocore Ltd High affinity HIV T cell receptors
CN101287831B (zh) 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
EP3766896A1 (en) 2011-09-15 2021-01-20 The United States of America, as represented by The Secretary, Department of Health and Human Services T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
EA201400447A1 (ru) * 2011-10-14 2014-09-30 Тева Фармасьютикал Австралия Пти Лтд. АНТИТЕЛА К CD1d
CN114891797A (zh) 2011-10-28 2022-08-12 瑞泽恩制药公司 T细胞受体基因修饰小鼠
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
ES2804538T3 (es) * 2013-01-29 2021-02-08 Max Delbrueck Centrum Fuer Molekulare Medizin Mdc Berlin Buch Moléculas de unión de alta avidez que reconocen MAGE-A1
WO2014160030A2 (en) 2013-03-13 2014-10-02 Health Research, Inc. Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen
EP3166647A4 (en) * 2014-07-09 2018-02-14 The Regents of the University of California Engineered invariant natural killer t (inkt) cells and methods of making and using thereof
WO2016022400A1 (en) 2014-08-04 2016-02-11 Fred Hutchinson Cancer Research Center T cell immunotherapy specific for wt-1
US10294304B2 (en) 2015-04-13 2019-05-21 Pfizer Inc. Chimeric antigen receptors targeting B-cell maturation antigen
FI3430030T3 (fi) 2016-03-16 2024-01-16 Immatics Biotechnologies Gmbh Transfektoituja t-soluja ja t-solureseptoreita käytettäviksi syöpien immunoterapiassa
EP3984559A1 (en) 2016-04-01 2022-04-20 Kite Pharma, Inc. Chimeric antigen and t cell receptors and methods of use

Also Published As

Publication number Publication date
AU2017246693B2 (en) 2022-07-21
PL3440105T3 (pl) 2022-08-29
LT3440105T (lt) 2022-05-25
PE20240693A1 (es) 2024-04-10
ES2914648T3 (es) 2022-06-15
US20230322895A1 (en) 2023-10-12
CA3020214A1 (en) 2017-10-12
US11505590B2 (en) 2022-11-22
JP7254519B2 (ja) 2023-04-10
JP2019516357A (ja) 2019-06-20
MA44608A (fr) 2019-02-13
DK3440105T3 (da) 2022-06-13
MX2018012318A (es) 2019-07-04
CN109563148B (zh) 2022-10-14
PE20190335A1 (es) 2019-03-07
PH12018502158A1 (en) 2019-07-15
AU2022256131A1 (en) 2022-11-24
AU2017246693A1 (en) 2018-11-22
EP4023668A1 (en) 2022-07-06
MA44608B1 (fr) 2022-06-30
EP3440105B1 (en) 2022-04-27
PT3440105T (pt) 2022-05-31
CL2018002859A1 (es) 2019-04-26
KR102473964B1 (ko) 2022-12-06
RU2018135248A3 (es) 2020-09-23
BR112018070741A2 (pt) 2019-02-12
RU2018135248A (ru) 2020-05-12
SI3440105T1 (sl) 2022-07-29
MY198621A (en) 2023-09-11
IL262144A (en) 2018-11-29
IL262144B2 (en) 2024-04-01
KR20180132844A (ko) 2018-12-12
MD3440105T2 (ro) 2022-09-30
EP3440105A1 (en) 2019-02-13
US20190092834A1 (en) 2019-03-28
RS63371B1 (sr) 2022-08-31
IL308831A (en) 2024-01-01
HRP20220865T1 (hr) 2022-10-14
IL262144B1 (en) 2023-12-01
WO2017175006A1 (en) 2017-10-12
SG11201808797XA (en) 2018-11-29
CR20180531A (es) 2019-06-13
HUE059159T2 (hu) 2022-10-28
CN109563148A (zh) 2019-04-02

Similar Documents

Publication Publication Date Title
CO2018011972A2 (es) Receptores de células t
ZA202306640B (en) T cell receptors
MY196179A (en) T Cell Receptors Specific for the NY-ESO-1 Tumor Antigen-Hla-A*02 Complex
CO2019011155A2 (es) Anticuerpos anti-ilt4 y fragmentos de unión a antígeno
CO2018010538A2 (es) Anticuerpos específicos del receptor de poliovirus humano (rvp)
CL2019003310A1 (es) Nuevos péptidos (seq id no:1) y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer. (divisional solicitud 201800124)
CO2018011668A2 (es) Neoantígenos y métodos de su uso
CL2020001181A1 (es) Nuevos receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos.
EA201992536A1 (ru) Tcr и пептиды
CL2017000311A1 (es) Anticuerpos anti-lag3 y fragmentos de unión a antígeno
CL2018002591A1 (es) Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón amicrocítico y otros tipos de cáncer
CL2017001071A1 (es) Método para la cuantificación absoluta de péptidos cancerígenos hla-restringidos procesados naturalmente
UY36539A (es) Proteínas de unión a icos
SA518391973B1 (ar) تركيبات ومجموعات تشتمل على مستقبلات خلية ناتجة عن عودة الارتباط الجيني وطرق ‏استخدام مستقبلات خلية ‏t‏- ‏ ناتجة عن عودة الارتباط الجيني ‏t-
CO2019013654A2 (es) Receptores de antígenos quiméricos que se dirigen a flt3
CL2019002093A1 (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer.
CL2018002610A1 (es) Linfocitos t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cáncer
CO2022000281A2 (es) Receptores de linfocitos t de mage-a4 y métodos de uso de estos
CO2018012497A2 (es) Anticuerpos de interferón beta y usos de los mismos
CL2019002878A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia y otros tipos de cáncer.
CL2019003426A1 (es) Nuevos péptidos (seq id n°174), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545)
CL2020001605A1 (es) Anticuerpos anti alfa-sinucleína.
BR112016002572A2 (pt) peptídeos
MX2022004906A (es) Moleculas de union especifica.
CL2019001537A1 (es) Nuevos receptores de células t y terapia inmunológica que los utiliza.